Hints and tips:
Related Special Reports
...The foundation’s philanthropic firepower has surged thanks to sales of diabetes and weight loss drugs by Novo Nordisk, in which the foundation holds a controlling stake through its subsidiary Novo Holdings...
...Fruergaard Jorgensen also said that Novo Nordisk’s efforts to develop some of its oral drugs would require much more active pharmaceutical ingredient than injectables....
...The bullish projection comes after Novo Holdings struck a $16.5bn deal on Monday to acquire Catalent, a pharmaceutical manufacturing company, before selling three Catalent sites for $11bn to Novo Nordisk...
...Despite Novo Nordisk and Eli Lilly’s lead, Steensberg believed there was space for others to develop weight-loss products....
...But she said if Novo Nordisk could develop such a treatment, it would be “ideal”....
...Novo Nordisk raised its guidance for 2024 as strong sales of its diabetes and weight loss drugs Ozempic and Wegovy drove profits above estimates....
...Novo Nordisk has been investing heavily in manufacturing capacity to meet soaring demand for Wegovy and Ozempic, which treats diabetes....
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...Eli Lilly is racing to secure the services of outsourcers to boost production of its obesity drug Zepbound, as the US pharmaceutical group rolls out its rival to Danish group Novo Nordisk’s blockbuster appetite...
...Ozempic” takes, referring to the diabetes and obesity medicine produced by Eli Lilly’s rival in the category, Novo Nordisk....
...Danish drugmaker Novo Nordisk has been “surprised” by the readiness of European consumers to pay for weight-loss drugs from their own pockets, as the region’s largest company invests in new supply to meet...
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
...Eli Lilly, maker of Mounjaro and the recently approved Zepbound, and Novo Nordisk have so far dominated the sector....
...Novo Nordisk is under pressure to increase production of both its filled injection pens and semaglutide, the active pharmaceutical ingredient used in Ozempic and Wegovy....
...Novo Nordisk is on a 37 times multiple and Eli Lilly on 59 times. Some estimates of the long-term market potential invite parallels with obesity drugs....
...“Once it is complete, which we anticipate around the end of 2024, Novo Nordisk will honour all existing contracts,” the company told the FT on Tuesday. Novo Holdings declined to comment....
...For that reason, the 2023 FT Person of the Year went to Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, the pharmaceutical company that brought these successful weight-loss drugs to market....
...Novo Nordisk: Shares in the Danish pharmaceutical company dropped 5 per cent after its US rival Amgen announced encouraging trial data on its experimental obesity drug MariTide....
...“That’s actually a fairly good frame of mind to have if you work in the pharma industry.” Novo Nordisk could invest for the very long term partly because of its unusual ownership structure....
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...Last month, Swiss pharmaceutical company Roche agreed an up to $3.1bn takeover of obesity drug developer Carmot Therapeutics....
...Read more about Novo Nordisk here....
...Novo Nordisk’s blockbuster offering Wegovy is expected to be approved for sale in China this year. That would be another boost for the Danish company....
...The US Federal Trade Commission has disputed more than 300 “bogus” patent listings filed for 20 brand name drugs, including Novo Nordisk’s blockbuster type two diabetes drug Ozempic, claiming they are aimed...
International Edition